本帖最后由 老马 于 2012-1-13 21:20 编辑
# A4 j! K/ ^( X0 C
( F0 Y& i# ]% H; s2 d2 ?爱必妥和阿瓦斯丁的比较# d) n5 ]( M/ A3 G1 o1 g
8 x( q4 G! J3 V$ ~
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/! I, d# v' `# K7 x, O( M: r
# q7 H I5 y3 _0 n
# ~8 b- u: `2 k9 H
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
# ~" @# _. ?( i& A==================================================& r- Y1 w8 f- u) L2 u4 ^
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 T+ K4 i' O) b" E2 K2 i) {$ lPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* B% k$ O$ p# T" O8 ^4 v9 r7 m7 zResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* N5 `, r! _, ~8 w( e) b4 b
|